Co-Infection with COVID-19 and Malaria in a Young Man

Mustafa Mahmood Eid
Emergency Department, Al Ain Hospital, Al Ain, UAE

Keywords
Coronavirus · Malaria · Fever · Coronavirus disease 2019

Abstract
Malaria is an infectious disease caused by Plasmodium protozoa, which can be fatal if not diagnosed and treated promptly. COVID-19 is a newly emerging disease that can affect different body systems; however, the respiratory system is mainly reported. This case describes a 20-year-old man who presented with fever and joint pain and was found to have P. falciparum malaria in addition to a positive SARS-CoV-2 test. The patient improved after he was treated with antimalarial medications in addition to supportive therapy. A co-infection of malaria and COVID-19 can occur. Thus, more studies need to be conducted on this co-infection. Besides, other diagnoses should be highly suspected in patients presenting with symptoms suggestive of SARS-CoV-2 infection, especially in vulnerable patients.

Introduction
Malaria is an infectious disease caused by Plasmodium protozoa, which is transmitted by a mosquito’s bite. It is severe and can be a fatal illness if not diagnosed and appropriately managed. Different types of plasmodium exist; however, Plasmodium falciparum is the most dangerous one. Fortunately, early diagnosis and appropriate treatment carry an excellent prognosis. The affected patient typically develops paroxysm of fever, fatigue, malaise, and body ache [1, 2]. SARS-CoV-2 is a new strain of coronavirus that started at the end of 2019 in China and spread worldwide [3]. The co-infection between malaria and COVID-19 is not understood or fully reported. In our case, the patient was found to have malaria with a positive SARS-CoV-2 test.

Case Presentation
A 20-year-old man presented to a healthcare facility complaining of intermittent fever and generalized body aches for 15 days. He denied any other complaints. His review of systems was negative. His examinations were unremarkable. Consequently, a set of blood tests, urinalysis, and chest X-ray were arranged. Moreover,
the SARS-CoV-2 nasopharyngeal swab was done and symptomatic management was commenced. His blood tests were unremarkable, apart from having a C-reactive protein of 28 (0–5) mg/L. At the same time, his chest radiograph and urinalysis were clear. Consequently, the patient improved and his fever subsided. He was discharged home on azithromycin and paracetamol. Two days later, the patient swab came positive for SARS-CoV-2, so he followed with a designated health facility for COVID-19. The patient was still complaining of fever spikes. Thus, the patient was sent to a quarantine facility on hydroxychloroquine and paracetamol, and antimalarial drugs ameliorate COVID-19 symptoms or if malaria’s complications increased the vulnerability is still unclear. Still, it is not known if SARS-CoV-2 infection reduced the immunity that led to a malaria flare-up and coughing continue to be the most common symptoms [5]. The disease spreads mostly through respiratory droplets during close contact, although the ability to spread by airborne is still questionable [6]. Also, some studies have documented other ways of transmission, mainly extra-pulmonary like fecal-oral [7].

Until now, there are no universal agreed guidelines for the treatment of COVID-19 disease. Nevertheless, several therapeutic regimens have been implanted. Of these, hydroxychloroquine, an antimalarial drug, has shown to have in vitro activity against the virus [8]. My hospital policy follows a regimen of hydroxychloroquine 400 mg BID on day 1, then 200 mg BID for 4 days, and an antiviral medication in severe cases or chest CT scan changes. All medications are given after the patient’s consent.

To the best of my knowledge, no previous studies documented the co-infection of *P. falciparum* malaria and COVID-19. Moreover, the pathophysiology behind this is still unclear. Still, it is not known if SARS-CoV-2 infection reduced the immunity that led to a malaria flare-up or if malaria’s complications increased the vulnerability to get COVID-19. In addition, it is not known whether antimalarial drugs ameliorate COVID-19 symptoms or mask them.

### Discussion

Malaria continues to be one of the leading infectious diseases that significantly impact the health system with a potential fatality, especially in tropical areas. Malaria diagnosis in non-endemic areas needs a careful history with a level of suspicion, especially in suggestive findings in a patient examination or investigation [4].

Although COVID-19 initially started in China, it is now a widespread pandemic across the world. Patients infected with SARS-CoV-2 can have variable presentations ranging from asymptomatic to severe respiratory failure, though extra-pulmonary symptoms can present. However, fever, shortness of breath, throat pain, and coughing continue to be the most common symptoms [5]. The disease spreads mostly through respiratory droplets during close contact, although the ability to spread by airborne is still questionable [6]. Also, some studies have documented other ways of transmission, mainly extra-pulmonary like fecal-oral [7].

Until now, there are no universal agreed guidelines for the treatment of COVID-19 disease. Nevertheless, several therapeutic regimens have been implanted. Of these, hydroxychloroquine, an antimalarial drug, has shown to have in vitro activity against the virus [8]. My hospital policy follows a regimen of hydroxychloroquine 400 mg BID on day 1, then 200 mg BID for 4 days, and an antiviral medication in severe cases or chest CT scan changes. All medications are given after the patient’s consent.

To the best of my knowledge, no previous studies documented the co-infection of *P. falciparum* malaria and COVID-19. Moreover, the pathophysiology behind this is still unclear. Still, it is not known if SARS-CoV-2 infection reduced the immunity that led to a malaria flare-up or if malaria’s complications increased the vulnerability to get COVID-19. In addition, it is not known whether antimalarial drugs ameliorate COVID-19 symptoms or mask them.

### Conclusion

Physicians should highly suspect other diseases and diagnoses in patients presenting with symptoms suggestive of SARS-CoV-2 infection, especially in vulnerable
patients. In addition, physicians should always bear in mind the possibility of a combination of COVID-19 and other diseases. Besides, more studies need to be conducted to understand the pathophysiology and any clinical significance of this co-infection.

Statement of Ethics

Written informed consent was obtained from the patient for publication of this case report.

Conflict of Interest Statement

The author has no conflicts of interest.

Funding Sources

I have no funding or support to declare.

Author Contributions

The author declares that he solely participated in the design, execution, and the writing of this case.

References

1 Malaria Fact Sheet. No. 94. Updated 2014 Mar; World [Internet]. Relief Web. 2020. Available from: https://reliefweb.int/report/world/malaria-fact-sheet-no-94-updated-march-2014.

2 Caraballo H, King K. Emergency department management of mosquito-borne illness: malaria, dengue, and west nile virus. Emerg Med Pract. 2014;16(5):1–23.

3 Eid M, Al-Kaisy M, Regeia W, Jiwa Khan H. The prognostic accuracy of neutrophil-lymphocyte ratio in COVID-19 patients. Front Emerg Med. 2021;5(1):e8.

4 Nadim B, Behrens RH. Malaria: an update for physicians. Infect Dis Clin North Am. 2012; 26(2):243–59.

5 Coronavirus disease 2019 (COVID-19): symptoms [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.

6 Transmission of SARS-CoV-2: implications for infection prevention precautions [Internet]. Who Int. 2020. Available from: https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precautionrecommendations.

7 Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal oral transmission. Gastroenterology. 2020;158(6):1518–9.

8 Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.